BTIG Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
Aclaris Therapeutics Analyst Ratings
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Hold Rating
Aclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic Review
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS), Celcuity (CELC) and Intuitive Surgical (ISRG)
Aclaris Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)
Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks
Aclaris Therapeutics Analyst Ratings
Aclaris Therapeutics (ACRS) Was Downgraded to a Hold Rating at BTIG
Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aclaris Therapeutics (ACRS) and Quanterix (QTRX)
Aclaris Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)
Aclaris Therapeutics Analyst Ratings
Buy Rating Justified by Aclaris Therapeutics' Strategic Focus and Robust Financial Management
Stifel Nicolaus Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)
Stifel Maintains Hold on Aclaris Therapeutics, Lowers Price Target to $1